The PACIFIC study, which evaluated the use of durvalamab after completion of chemotherapy and radiation (both sequential and concurrent) is a landmark trial demonstrating improved survival for those receiving immunotherapy. The design of the study required that durvalamab commence within 42 days of ...

In general, I would follow the entry/eligibility criteria as described in the PACIFIC trial - i.e. up to 42 days/six weeks after completion of chemoradiation (last dose of radiation). In fact, in the supplementary data from the 2018 NEJM report, there was a trend towards improvement in OS with trea...